Cloning, Expression, and Refolding of PPE17 Protein of Mycobacterium Tuberculosis as a Promising Vaccine Candidate.

Gene expression Mycobacterium tuberculosis Protein refolding Rv1168c protein

Journal

Iranian journal of medical sciences
ISSN: 0253-0716
Titre abrégé: Iran J Med Sci
Pays: Iran
ID NLM: 8104374

Informations de publication

Date de publication:
Jan 2019
Historique:
entrez: 23 1 2019
pubmed: 23 1 2019
medline: 23 1 2019
Statut: ppublish

Résumé

Tuberculosis as a global health problem requires special attention in the contexts of prevention and control. Subunit vaccines are promising strategies to protect burdens of tuberculosis via increasing the BCG protection. The present study aimed to design a vaccine study by means of high-throughput expression and correct refolding of recombinant protein PPE17. We aimed to clone, express, and refold PPE17 protein of The expressed recombinant protein was entirely found in insoluble form (inclusion bodies). The insoluble protein was denatured in 6M guanidine-HCl and refolded by descending denaturant concentration dialysis. Moreover, the recombinant protein was purified by Ni-NTA column chromatography. The changing temperature had no effects on solubilizing protein and the maximum expression was achieved at 0.5 mM concentration of isopropyl-D-thiogalactopyranoside (IPTG) induction. Bacterial expression system is a timesaving tool and refolding by descending denaturant concentration dialysis is a rapid and reliable method.

Sections du résumé

BACKGROUND BACKGROUND
Tuberculosis as a global health problem requires special attention in the contexts of prevention and control. Subunit vaccines are promising strategies to protect burdens of tuberculosis via increasing the BCG protection. The present study aimed to design a vaccine study by means of high-throughput expression and correct refolding of recombinant protein PPE17.
METHODS METHODS
We aimed to clone, express, and refold PPE17 protein of
RESULTS RESULTS
The expressed recombinant protein was entirely found in insoluble form (inclusion bodies). The insoluble protein was denatured in 6M guanidine-HCl and refolded by descending denaturant concentration dialysis. Moreover, the recombinant protein was purified by Ni-NTA column chromatography. The changing temperature had no effects on solubilizing protein and the maximum expression was achieved at 0.5 mM concentration of isopropyl-D-thiogalactopyranoside (IPTG) induction.
CONCLUSION CONCLUSIONS
Bacterial expression system is a timesaving tool and refolding by descending denaturant concentration dialysis is a rapid and reliable method.

Identifiants

pubmed: 30666076
pmc: PMC6330522

Types de publication

Journal Article

Langues

eng

Pagination

53-59

Références

J Chromatogr A. 1999 Dec 24;864(2):229-36
pubmed: 10669290
Trends Immunol. 2001 Mar;22(3):160-8
pubmed: 11286732
Protein Expr Purif. 2003 Mar;28(1):1-8
pubmed: 12651100
Protein Expr Purif. 2004 Jul;36(1):53-60
pubmed: 15177284
Tuberculosis (Edinb). 2004;84(3-4):205-17
pubmed: 15207490
Tuberculosis (Edinb). 2004;84(3-4):239-46
pubmed: 15207493
Microb Cell Fact. 2004 Sep 2;3(1):11
pubmed: 15345063
Protein Expr Purif. 2005 Feb;39(2):184-8
pubmed: 15642469
Anal Biochem. 2006 Apr 1;351(1):122-7
pubmed: 16434014
Gene. 1991 Dec 1;108(1):1-6
pubmed: 1761218
Nat Rev Microbiol. 2007 Nov;5(11):883-91
pubmed: 17922044
Clin Vaccine Immunol. 2008 Jun;15(6):974-80
pubmed: 18400969
Lancet. 2010 Jun 12;375(9731):2110-9
pubmed: 20488515
Sci Transl Med. 2010 Oct 13;2(53):53ra74
pubmed: 20944089
Paediatr Respir Rev. 2011 Mar;12(1):46-51
pubmed: 21172675
Lancet Infect Dis. 2011 Aug;11(8):633-40
pubmed: 21798463
Trends Immunol. 2012 Jul;33(7):373-9
pubmed: 22560865
Protein Expr Purif. 2013 Dec;92(2):223-9
pubmed: 24056255
Front Microbiol. 2014 Sep 15;5:486
pubmed: 25309524
Iran J Microbiol. 2016 Aug;8(4):226-231
pubmed: 28210460
Protein Eng. 1995 Feb;8(2):201-5
pubmed: 7630889
Protein Expr Purif. 1997 Mar;9(2):211-8
pubmed: 9056486

Auteurs

Adel Najafi (A)

Antimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Mohsen Tafaghodi (M)

Nanotechnology Research Center, Pharmaceutical Department, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Mojtaba Sankian (M)

Immunology Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Yousef Amini (Y)

Department of Microbiology and Virology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.

Kiarash Ghazvini (K)

Antimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Classifications MeSH